United Kingdom · Question · Written question
HL HL9841
Vorasidenib
Introduced
4 September 2023
Last action
7 September 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
7 September 2023
Summary
To ask His Majesty's Government what assessment they have made of the efficacy of Vorasidenib for the treatment of brain tumours.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
4 September 2023
Written question
To ask His Majesty's Government what assessment they have made of the efficacy of Vorasidenib for the treatment of brain tumours.
Source: Lords
7 September 2023
Answer
In the United Kingdom, medicines need to have a licence before they can be marketed, and these are granted by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA has not issued a scientific opinion for Vorasidenib. Should an applicati...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-09-04/HL9841
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1657642
- uk · wq-1657642 · source updated 7 September 2023